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Background
The accumulation of eosinophils in lung tissue is a hall-
mark of asthma, and it is believed that eosinophils play a
crucial pathogenic role in allergic inflammation. Prostag-
landin (PG) E2 exerts anti-inflammatory and broncho-
protective mechanisms in asthma, but the underlying
mechanisms have remained unclear. We have shown pre-
viously that PGE2 and the EP2 receptor agonist butaprost
inhibit eosinophil trafficking in vitro and in vivo.
Methods
Human eosinophils were purified by negative magnetic
selection from peripheral blood. Cell migration was deter-
mined in microBoyden chemotaxis chambers. Ca2+ flux
and expression of cell surface markers was recorded by
flow cytometry. EP4  receptor expression was demon-
strated by immunostaining.
Results
The chemotaxis of eosinophils towards eotaxin and C5a
was attenuated by the EP4 agonist ONO-AE1-329, and the
EP4 antagonists ONO-AE3-208 and GW627368x partially
reversed the inhibitory effect of PGE2  on eosinophil
migration. ONO-AE1-329, and also PGE2, but not but-
aprost, inhibited the Ca2+ flux and the production of reac-
tive oxygen species in eosinophils. ONO-AE1-329 also
inhibited eosinophil degranulation and the up-regulation
of the adhesion molecule CD11b. Selective kinase inhibi-
tors revealed that the inhibitory effect of EP4 stimulation
on eosinophil migration depended upon activation of
phosphatidylinositol 3-kinase and protein kinase C, but
not cAMP. Immunostaining showed that human eosi-
nophils express EP4 receptors and that EP4 receptor expres-
sion in the murine lungs is prominent in airway
epithelium, and after allergen challenge, in peribronchial
infiltrating leukocytes.
Conclusion
These data show that EP4  receptor agonists potently
inhibit eosinophil trafficking and activation, and might
hence be a useful therapeutic option in eosinophilic dis-
eases.
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